AlloVir, Inc. - Common Stock (ALVR)

Allovir Inc is a biotechnology company focused on developing innovative cell therapies aimed at treating viral infections in immunocompromised patients

The company leverages its proprietary technology platform to produce potential therapies that can enhance the immune response against viral pathogens, particularly in individuals with weakened immune systems, such as those undergoing stem cell transplants or other forms of immunosuppression. By harnessing the power of T-cells, Allovir aims to provide effective treatment options for viral infections that currently have limited therapeutic alternatives, ultimately improving patient outcomes and quality of life.